BOSTON, MA and GERMANTOWN, MD – January 10, 2017 – ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, and Intrexon Corporation (NYSE:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the
NEW YORK, Oct 22, 2009 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 8 th Annual BIO Investor Forum on Thursday, October 29, 2009 at 10:00 am PT at the Palace Hotel in San Francisco, CA. Dr.
NEW YORK, Jun 02, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it will present at the following investor conferences on Wednesday June 9, 2010: 9 th Annual Needham Healthcare Conference New York, NY 10:40 a.m. ET Jefferies 2010 Global Life Sciences Conference
ZIOPHARM Oncology is pleased to share a story from the Ann & Robert H. Lurie Children's Hospital in Chicago on the Ad-RTS-hIL-12 plus veledimex clinical trial for pediatric patients with brain cancer. As we announced last week, Stewart Goldman, M.D., Division Head Hematology-Oncology,
BARCELONA, Spain, Sep 25, 2007 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today the presentation of data from ongoing clinical trials of darinaparsin (ZIO-101) to treat advanced hematological malignancies. The data were presented yesterday at the 14th Annual European
NEW YORK, Jan 27, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, has been invited to participate at the 2 nd International Conference on Drug Discovery and Therapy in Dubai, United Arab Emirates as: Chairman of
NEW YORK, Feb 08, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, has been invited to present at the Inaugural UCL One Day Finance Conference to be held on February 15 th .
